<DOC>
	<DOCNO>NCT01783301</DOCNO>
	<brief_summary>The overall objectives trial : - To explore efficacy safety use either antral follicle count ( AFC ) anti-Mullerian hormone ( AMH ) guide start dose GONAL-f® ovarian stimulation Assisted Reproductive Technology ( ART ) . - To assess difference ovarian response clinical pregnancy rate subject different AFC AMH level undergo ART .</brief_summary>
	<brief_title>Anti-Mullerian Hormone ( AMH ) Versus Antral Follicle Count ( AFC ) Guided rFSH Dosing Study</brief_title>
	<detailed_description>Trial design This trial prospective , Phase IV 2 arm trial explore efficacy safety use either AFC AMH guide start GONAL-f® dose stimulation treatment subject undergoing ART . Throughout trial period start routine ART cycle , investigator propose trial potential subject . All subject agree participate trial must sign consent form , irrespective whether ultimately agree dose determine study protocol . Eligible subject randomise block 4 site via computer generate random number list either AFC guide arm ( control ) AMH guide arm ( treatment ) . The starting dos GONAL-f® arm base study algorithm , use AFC AMH guidance . The investigator enter initiate ovarian stimulation individualise GONAL-f® dose specific subject . This maintain first 5 day stimulation dose modify base investigator decision accordance site 's routine clinical practice . Trial Population Female partner infertile couple require Assisted Reproductive Technology ( ART ) treatment . Data Analysis Statistics The primary end-point proportion patient desire number retrieve oocyte ( 8-12 ) compare 2 arm use chi -square test . The null hypothesis difference 2 arm primary end-point , p level set p=0.05 . The secondary end-points also compare 2 arm use either Student 's test anova test .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Starting treatment GONALf® accord decision investigator accordance indication dose recommendation Age &lt; 40 year time GONALf® dose BMI &lt; 28 kg/m2 An early follicular phase ( Day 24 ) serum level basal FSH ≤12 IU/L measure site 's laboratory take within 2 month prior downregulation start Receiving long GonadotropinReleasing Hormone ( GnRH ) agonist protocol ( start day 21 precede cycle day hCG ) Agreement participate study , disclose medical event investigator . The subject must willing able comply protocol requirement duration study . Have give write informed consent understand subject may withdraw consent time without prejudice future medical care . Simultaneous participation interventional clinical trial . Concommitant use either Luteinizing Hormone human menopausal gonadotropin/urinary FSH preparation study cycle</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>follicle stimulate hormone</keyword>
	<keyword>ovarian stimulation</keyword>
	<keyword>antimullerian hormone</keyword>
	<keyword>antral follicle count</keyword>
	<keyword>assist reproductive technology</keyword>
</DOC>